Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
暂无分享,去创建一个
Sara A. Berg | R. Clark | A. Maity | J. Plastaras | Ellen J. Kim | A. Rook | D. Lewis | J. Teague | M. Wysocka | B. Benoit | Joseph S. Durgin | Joanne Inverso | C. Vittorio | N. Jariwala | S. Samimi | P. Haun | J. Rosenthal | J. Villaseñor-Park | Kevin Zhang | Christina A. Del Guzzo | J. Villaseñor‐Park | Christina Del Guzzo
[1] H. Prince,et al. Lack of Durable Remission with Conventional-Dose Total Skin Electron Therapy for the Management of Sezary Syndrome and Multiply Relapsed Mycosis Fungoides , 2019, Cancers.
[2] C. Klemke,et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. , 2017, European journal of cancer.
[3] M. Chowdhary,et al. Total Skin Electron Beam Therapy in the Treatment of Mycosis Fungoides: A Review of Conventional and Low-Dose Regimens. , 2016, Clinical lymphoma, myeloma & leukemia.
[4] M. Duvic,et al. Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. , 2015, Clinical lymphoma, myeloma & leukemia.
[5] S. Lade,et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. , 2015, Blood.
[6] Wei Wei,et al. Long-term Outcomes of 1,263 Patients with Mycosis Fungoides and Sézary Syndrome from 1982 to 2009 , 2012, Clinical Cancer Research.
[7] M. Lefranc. IMGT, the International ImMunoGeneTics Information System. , 2011, Cold Spring Harbor protocols.
[8] R. Advani,et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). , 2011, Journal of the American Academy of Dermatology.
[9] J. Scarisbrick,et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Boer,et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. , 2009, Blood.
[11] Ellen J. Kim,et al. Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome. , 2008, Journal of the American Academy of Dermatology.
[12] Nicola Pimpinelli,et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.
[13] T. Kuzel,et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Marie-Paule Lefranc,et al. IMGT, The International ImMunoGeneTics Information System, http://imgt.cines.fr. , 2004, Methods in molecular biology.
[15] W. Sterry,et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. , 1998, Blood.